Literature DB >> 30226142

Case Report: Ivermectin and Albendazole Plasma Concentrations in a Patient with Disseminated Strongyloidiasis on Extracorporeal Membrane Oxygenation and Continuous Renal Replacement Therapy.

Carl Boodman1, Yashpal S Chhonker2, Daryl J Murry2, Allison Mah1, Jennifer Grant3,1, Theodore Steiner1, Michael Libman4, Cesilia Nishi5, Marthe Charles3.   

Abstract

Disseminated strongyloidiasis is often fatal, despite treatment with oral albendazole and parenteral ivermectin (IVM). Here, we report elevated plasma IVM and albendazole sulfoxide concentrations in the context of extracorporeal membrane oxygenation and continuous renal replacement therapy in a patient with disseminated strongyloidiasis treated with subcutaneous IVM and nasogastric albenzadole. Despite elevated drug plasma concentrations, live filariform larvae were detected in endotracheal aspirates after 2 weeks of treatment.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30226142      PMCID: PMC6221216          DOI: 10.4269/ajtmh.18-0487

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  29 in total

Review 1.  The pharmacokinetics and interactions of ivermectin in humans--a mini-review.

Authors:  Aránzazu González Canga; Ana M Sahagún Prieto; M José Diez Liébana; Nélida Fernández Martínez; Matilde Sierra Vega; Juan J García Vieitez
Journal:  AAPS J       Date:  2008-01-25       Impact factor: 4.009

Review 2.  Albendazole.

Authors:  P Venkatesan
Journal:  J Antimicrob Chemother       Date:  1998-02       Impact factor: 5.790

3.  Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.

Authors:  Edward K Thomsen; Nelly Sanuku; Manasseh Baea; Samson Satofan; Elit Maki; Bart Lombore; Mark S Schmidt; Peter M Siba; Gary J Weil; James W Kazura; Lawrence L Fleckenstein; Christopher L King
Journal:  Clin Infect Dis       Date:  2015-10-20       Impact factor: 9.079

Review 4.  Clinical review: Extracorporeal membrane oxygenation.

Authors:  Luciano Gattinoni; Eleonora Carlesso; Thomas Langer
Journal:  Crit Care       Date:  2011-12-08       Impact factor: 9.097

5.  Liquid chromatographic assay of ivermectin in human plasma for application to clinical pharmacokinetic studies.

Authors:  Dennis Kitzman; She-Yi Wei; Lawrence Fleckenstein
Journal:  J Pharm Biomed Anal       Date:  2005-10-19       Impact factor: 3.935

6.  In vitro analysis of albendazole sulfoxide enantiomers shows that (+)-(R)-albendazole sulfoxide is the active enantiomer against Taenia solium.

Authors:  Adriana Paredes; Tiago de Campos Lourenço; Miguel Marzal; Andrea Rivera; Pierre Dorny; Siddhartha Mahanty; Cristina Guerra-Giraldez; Hector H García; Theodore E Nash; Quezia B Cass
Journal:  Antimicrob Agents Chemother       Date:  2012-12-10       Impact factor: 5.191

7.  Serum ivermectin levels after enteral and subcutaneous administration for Strongyloides hyperinfection: a case report.

Authors:  Jonathan D Grein; Glenn E Mathisen; Suzanne Donovan; Lawrence Fleckenstein
Journal:  Scand J Infect Dis       Date:  2010-03

8.  Clinical pharmacokinetics of albendazole in patients with brain cysticercosis.

Authors:  H Jung; M Hurtado; M Sanchez; M T Medina; J Sotelo
Journal:  J Clin Pharmacol       Date:  1992-01       Impact factor: 3.126

Review 9.  Severe strongyloidiasis: a systematic review of case reports.

Authors:  Dora Buonfrate; Ana Requena-Mendez; Andrea Angheben; Jose Muñoz; Federico Gobbi; Jef Van Den Ende; Zeno Bisoffi
Journal:  BMC Infect Dis       Date:  2013-02-08       Impact factor: 3.090

10.  Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation.

Authors:  Kiran Shekar; Jason A Roberts; Charles I Mcdonald; Stephanie Fisquet; Adrian G Barnett; Daniel V Mullany; Sussan Ghassabian; Steven C Wallis; Yoke L Fung; Maree T Smith; John F Fraser
Journal:  Crit Care       Date:  2012-10-15       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.